Group 1: New Stock Subscription - Bibet - Bibet (688759.SH) is a biopharmaceutical company focused on innovative drug development, particularly in oncology, autoimmune diseases, and metabolic diseases [1][4] - The company has a market capitalization of 6.401 billion yuan and an issue price of 17.78 yuan per share, with an expected price-to-earnings ratio of 31.83 [4] - Bibet's research pipeline includes one approved innovative drug, BEBT-908, and several others in various clinical trial phases, with a significant focus on unmet clinical needs [5][6][7] Group 2: Financial Performance and Funding - Bibet has reported net losses of 0.0188 billion yuan, 0.0173 billion yuan, and 0.0056 billion yuan over the past three years, indicating ongoing financial challenges [8] - The company plans to allocate 9.49 billion yuan (47.35%) of its raised funds to new drug research and development, 5.55 billion yuan (27.71%) to the construction of a research center, and 5.00 billion yuan (24.94%) for working capital [4] Group 3: New Stock Listing - Daosheng Tianhe - Daosheng Tianhe (601026.SH) is a national high-tech enterprise specializing in the research, production, and sales of new materials, particularly epoxy resins and polyurethane [1][11] - The company has a market capitalization of 3.943 billion yuan and an issue price of 5.98 yuan per share, with a price-to-earnings ratio of 29.05 [11] - Daosheng Tianhe is recognized as a leading supplier of materials for wind turbine blades and has established stable relationships with major industry players [14][15] Group 4: Financial Performance and Market Position - Daosheng Tianhe's revenue for 2022, 2023, and 2024 was 3.436 billion yuan, 3.202 billion yuan, and 3.238 billion yuan, with net profits of 0.11 billion yuan, 0.155 billion yuan, and 0.155 billion yuan respectively [15] - The company has been recognized as a national-level "little giant" enterprise and has obtained 69 patents, including 38 invention patents [15]
肿瘤小分子创新药企今日申购，风电环氧树脂龙头上市丨打新早知道